A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
The Trump administration is kicking off the year with yet another round of Medicare drug price negotiations.
But for the first time, they include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer and arthritis.
These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions.
The negotiated prices for the 15 drugs chosen this year will take effect in 2028. They reflect the highest-spending medications on a list of 50 top negotiation-eligible drugs, which the administration also released in full.
